Topotecan

Drug Profile

Topotecan

Alternative Names: Hycamtin; NK-211; Nogitecan; NSC 609699; SKF 104864; Topotecan hydrochloride

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Nippon Kayaku; Novartis; SCRI Development Innovations
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • Phase III Brain cancer

Most Recent Events

  • 18 Feb 2016 Investigation in Small cell lung cancer (Combination therapy) in USA (PO)
  • 18 Feb 2016 Phase-I/II clinical trials in Ovarian cancer (Combination therapy) in USA (PO)
  • 02 Mar 2015 Novartis acquires Topotecan from GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top